[go: up one dir, main page]

PE20060656A1 - COMPUESTOS DE IMIDAZO[1,2-a]PIRIDINIL COMO MODULADORES DE LA ACTIVIDAD DE QUIMIOQUINAS - Google Patents

COMPUESTOS DE IMIDAZO[1,2-a]PIRIDINIL COMO MODULADORES DE LA ACTIVIDAD DE QUIMIOQUINAS

Info

Publication number
PE20060656A1
PE20060656A1 PE2005001008A PE2005001008A PE20060656A1 PE 20060656 A1 PE20060656 A1 PE 20060656A1 PE 2005001008 A PE2005001008 A PE 2005001008A PE 2005001008 A PE2005001008 A PE 2005001008A PE 20060656 A1 PE20060656 A1 PE 20060656A1
Authority
PE
Peru
Prior art keywords
methyl
imidazo
quinolinyl
pyridin
tetrahydro
Prior art date
Application number
PE2005001008A
Other languages
English (en)
Inventor
Kristjan Gudmundsson
Sharon Davis Boggs
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PE20060656A1 publication Critical patent/PE20060656A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/08Antiseborrheics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DEIMIDAZO[1,2-a]PIRIDINIL DE FORMULA (I), EN DONDE t ES DE 0 A 2; CADA R ES INDEPENDIENTEMENTE H, ALQUIL, ENTRE OTROS; CADA R1 ES HALOGENO, HALOALQUIL, ENTRE OTROS; n ES DE O A 2; R2 ES H, ALQUIL, HALOALQUIL, ALQUIL, RaOR5, RaCICLOALQUIL, ENTRE OTROS; CADA R4 ES HALOGENO, HALOALQUILO, ENTRE OTROS; m ES DE 0 A 2; CADA R5 ES INDEPENDIENTEMENTE H, ALQUIL, ALQUENIL, CICLOALQUILO O Ay; p ES DE O A 1; Y ES -NR10-, -O-, -C(O)NR10-, ENTRE OTROS; X ES -RaN(R10)2, -AyRaN(R10)2, -RaAyRaN(R10)2, -Het, RaHet, -HetN(R10)2, ENTRE OTROS, SON PREFERIDOS: (5-(4-METIL-1-PIPERAZINIL)-2-{[METIL(5,6,7,8-TETRAHIDRO-8-QUINOLINIL)AMINO]METIL}IMIDAZO[1,2-a]PIRIDIN-3-IL)METANOL, [2-({{(1S)-1-[4-(METILOXI)FENIL]ETIL}[(8S)-(5,6,7,8-TETRAHIDRO-8-QUINOLINIL)AMINO}METIL)-4-(4-METIL-1-PIPERAZINIL)IMIDAZO[1,2-a]PIRIDIN-3-IL}METANOL, [5-[(3R)-3-(DIETILAMINO)-1-PIRROLIDINIL]-2-({METIL[(8S)-5,6,7,8-TETRAHIDRO-8-QUINOLINIL]AMINO}METIL)IMIDAZO[1,2-a]PIRIDIN-3-IL]METANOL, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCESO DE PREPARACION Y UNA COMPOSICION FARAMACEUTICA. ESTOS COMPUESTOS INHIBEN LA INTERACCION DE gp 120 YA SEA CON CCR5/CD4 O CXCR4/CD4, POR LO QUE SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES CAUSADAS POR LA INFECCION DE CEPAS M-TROPICAS O T-TROPICAS DE VIH
PE2005001008A 2004-09-02 2005-09-01 COMPUESTOS DE IMIDAZO[1,2-a]PIRIDINIL COMO MODULADORES DE LA ACTIVIDAD DE QUIMIOQUINAS PE20060656A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60674204P 2004-09-02 2004-09-02
US61076504P 2004-09-17 2004-09-17

Publications (1)

Publication Number Publication Date
PE20060656A1 true PE20060656A1 (es) 2006-08-24

Family

ID=36000724

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2005001008A PE20060656A1 (es) 2004-09-02 2005-09-01 COMPUESTOS DE IMIDAZO[1,2-a]PIRIDINIL COMO MODULADORES DE LA ACTIVIDAD DE QUIMIOQUINAS
PE2005001007A PE20060712A1 (es) 2004-09-02 2005-09-01 Compuestos derivados de quinolinamina como moduladores del receptor de quimioquina

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2005001007A PE20060712A1 (es) 2004-09-02 2005-09-01 Compuestos derivados de quinolinamina como moduladores del receptor de quimioquina

Country Status (16)

Country Link
US (2) US20070232615A1 (es)
EP (2) EP1799671A4 (es)
JP (2) JP2008511669A (es)
KR (2) KR20070049682A (es)
AR (2) AR050302A1 (es)
AU (2) AU2005279835A1 (es)
BR (1) BRPI0514881A (es)
CA (2) CA2579059A1 (es)
IL (1) IL181419A0 (es)
MA (1) MA28872B1 (es)
MX (2) MX2007002679A (es)
NO (2) NO20071366L (es)
PE (2) PE20060656A1 (es)
RU (2) RU2352567C2 (es)
TW (2) TW200621754A (es)
WO (2) WO2006026703A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007002679A (es) * 2004-09-02 2007-05-16 Smithkline Beecham Corp Compuestos quimicos.
PE20070946A1 (es) * 2006-01-25 2007-10-16 Smithkline Beecham Corp COMPUESTOS DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA COMO MODULADORES DEL RECEPTOR DE QUIMIOQUINA (CXCR4)
JP5257068B2 (ja) 2006-05-16 2013-08-07 小野薬品工業株式会社 保護されていてもよい酸性基を含有する化合物およびその用途
US20090325992A1 (en) 2006-07-31 2009-12-31 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
US7767826B2 (en) * 2007-10-05 2010-08-03 Pharmatech International, Inc. Process for the synthesis of L-(+)-ergothioneine
US20100292232A1 (en) * 2007-11-09 2010-11-18 Daniel Elleder Non-nucleoside reverse transcriptase inhibitors
CN102675305B (zh) * 2011-03-08 2014-11-12 中国科学院上海药物研究所 一类咪唑并吡啶类化合物及其制备方法和用途
CN103570683B (zh) * 2012-07-30 2018-04-17 中国科学院上海药物研究所 多取代胺类化合物及其制备方法和用途
RS59534B1 (sr) 2014-02-13 2019-12-31 Incyte Corp Ciklopropilamini kao lsd1 inhibitori
PH12020552066A1 (en) 2014-02-13 2022-05-11 Incyte Corp Cyclopropylamines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
EP3626720A1 (en) 2015-04-03 2020-03-25 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
MX389824B (es) 2015-08-12 2025-03-20 Incyte Holdings Corp Sales de un inhibidor de dimetilasa 1 especifica para lisina (lsd1).
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
JP6864296B2 (ja) 2015-12-14 2021-04-28 エックス4 ファーマシューティカルズ, インコーポレイテッド がんを処置する方法
KR102738306B1 (ko) * 2015-12-15 2024-12-03 브리스톨-마이어스 스큅 컴퍼니 Cxcr4 수용체 길항제
EP3393468B1 (en) 2015-12-22 2022-09-14 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
WO2017177230A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
CA3027495A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CA3027498A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CN109641838A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
IL309069A (en) * 2017-02-21 2024-02-01 Univ Emory CXCR4 cytokine receptor modulators and related uses
KR102678977B1 (ko) * 2017-09-25 2024-06-28 씨젠테크 (쑤저우, 차이나) 컴퍼니 리미티드 Cxcr4 저해제로서 헤테로아릴 화합물, 그 조성물 및 이용 방법
US11396501B2 (en) * 2017-09-25 2022-07-26 Cgenetech (Suzhou, China) Co., Ltd. Heteroaryl compounds as CXCR4 inhibitors, composition and method using the same
EP3768256A4 (en) 2018-03-19 2021-11-24 Emory University PANTROPIC ENTRY INHIBITORS
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
CN115515585A (zh) 2020-03-10 2022-12-23 X4 制药有限公司 用于治疗中性粒细胞减少症的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225152A (en) * 1987-07-17 1990-04-26 Janssen Pharmaceutica Nv Heterocyclically substituted piperidinyl benzamides as pharmaceuticals
JP2004512336A (ja) * 2000-09-15 2004-04-22 アノーメッド インコーポレイティド ケモカインレセプター結合複素環式化合物
SG126006A1 (en) * 2000-09-15 2006-10-30 Anormed Inc Chemokine receptor binding heterocyclic compounds
DE60137944D1 (de) * 2000-09-15 2009-04-23 Anormed Inc Chemokin rezeptor bindenden heterozyklische verbindungen
EP1752455B1 (en) * 2000-09-15 2010-11-10 Anormed Inc. Chemokine receptor binding heterocyclic compounds
CA2467718C (en) * 2001-12-21 2011-04-26 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
EP1613613B1 (en) * 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
MX2007002679A (es) * 2004-09-02 2007-05-16 Smithkline Beecham Corp Compuestos quimicos.
EP1793825A4 (en) * 2004-09-24 2009-12-09 Smithkline Beecham Corp CHEMICAL COMPOUNDS
US20080234318A1 (en) * 2005-08-31 2008-09-25 Kristjan Gudmundsson Chemical Compounds

Also Published As

Publication number Publication date
US20070254910A1 (en) 2007-11-01
AR050302A1 (es) 2006-10-11
KR20070049682A (ko) 2007-05-11
EP1799671A2 (en) 2007-06-27
RU2007106779A (ru) 2008-10-10
JP2008511668A (ja) 2008-04-17
MA28872B1 (fr) 2007-09-03
NO20071418L (no) 2007-05-31
CA2579059A1 (en) 2006-03-16
WO2006026703A8 (en) 2006-05-26
TW200612921A (en) 2006-05-01
IL181419A0 (en) 2007-07-04
KR20070053313A (ko) 2007-05-23
EP1784185A4 (en) 2009-06-03
TW200621754A (en) 2006-07-01
AR051565A1 (es) 2007-01-24
JP2008511669A (ja) 2008-04-17
CA2578746A1 (en) 2006-03-09
WO2006026703A2 (en) 2006-03-09
AU2005282753A1 (en) 2006-03-16
MX2007002615A (es) 2007-04-27
AU2005279835A1 (en) 2006-03-09
WO2006026703A3 (en) 2006-10-05
US20070232615A1 (en) 2007-10-04
BRPI0514881A (pt) 2008-06-24
RU2352567C2 (ru) 2009-04-20
MX2007002679A (es) 2007-05-16
RU2007106780A (ru) 2008-10-10
NO20071366L (no) 2007-05-31
EP1784185A2 (en) 2007-05-16
EP1799671A4 (en) 2009-06-10
WO2006028896A3 (en) 2006-04-27
WO2006028896A2 (en) 2006-03-16
RU2351592C2 (ru) 2009-04-10
PE20060712A1 (es) 2006-08-24

Similar Documents

Publication Publication Date Title
PE20060656A1 (es) COMPUESTOS DE IMIDAZO[1,2-a]PIRIDINIL COMO MODULADORES DE LA ACTIVIDAD DE QUIMIOQUINAS
PE20060646A1 (es) Derivados de bencimidazol como moduladores de la actividad de quimioquinas
MY134223A (en) Tropane derivatives as ccr5 modulators
PE20091818A1 (es) DERIVADOS POLISUSTITUIDOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
PE20080895A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20070946A1 (es) COMPUESTOS DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA COMO MODULADORES DEL RECEPTOR DE QUIMIOQUINA (CXCR4)
PE20080677A1 (es) Inhibidores de pirrolotriazina cinaza
PE20060210A1 (es) 8-[3-amino-piperidin-1-il]-xantinas como inhibidores de dpp-iv
PE20060150A1 (es) Antagonistas de cgrp seleccionados, composiciones farmaceuticas y procedimiento para su preparacion
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
MA31766B1 (fr) Composés organiques
PE20060316A1 (es) Derivados de prolina como inhibidores de dipeptidil peptidasa-iv
PE20080139A1 (es) Compuestos de pirrolotriazina anilina como inhibidores de cinasa
PE20050867A1 (es) DERIVADOS DE PIPERAZINA COMO INHIBIDORES DE LA INTERACCION DE gp 120 CON CD4
BR0312572A (pt) Derivados de azabiciclo como antagonistas de receptores muscarìnicos
PE20071104A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv (dpp-4)
PE20080209A1 (es) Derivados de glicina como inhibidores de prolil hidroxilasa
ES2177422B1 (es) Composiciones acaricidas.
GEP20084505B (en) 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
PE20060306A1 (es) Compuestos de heteroaril-amida sustituida
ZA200404022B (en) Quinazoline(di) ones for invertebrate pest control
PE20081341A1 (es) Inhibidores de la actividad de la akt
MA29532B1 (fr) Formes cristallines et autres de sels d'acide lactique 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one
PE20040687A1 (es) Quinolinas sustituidas como antagonistas del receptor ccr5
SI3075726T1 (en) DERIVATIVES OF UREA OR ITS PHARMACOLOGICAL RECRUITABLE SALTS USED AS FORMIL PEPTIDAL RECEPTOR LIKE 1 (FPRL-1) AGONISTS

Legal Events

Date Code Title Description
FC Refusal